Dr. Jonathan Schoeff
speaker
2,131 appearances
2 recordings
1 series
first heard Jul 2026
last heard 28 Jul
Dr. Jonathan Schoeff’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 2 in all, peaking in Jul 2026 with 2.
Appearances
I am not aware of any other single agent relative to all-cause mortality, because we talked about grip strength.
We'll get into all these numbers.
So all-cause mortality, if you say, well, what is longevity?
Well, it's preventing or reducing risk of all-cause mortality.
That's the ultimately longevity agent, okay?
Is that fair?
So in a diabetic...
to 400 higher likelihood to die period all cause mortality but look at the impact of type 2 diabetes on the risk of cardiovascular death 2.5 to 3 times higher than the average population
almost on par with familial hypercholesterolemia.
We all know cholesterol is bad.
We can get into that conversation.
Statins for everybody.
And I think there's a rational use to it all.
But nevertheless, we're so hung up on cardiovascular death.
leading cause of death in the United States today, which by the way, it's just barely above cancer.
But one single agent exponentially increases the risk of death from heart attack, stroke, early onset dementia, cancer, and that's diabetes.
To me, that's the smoking gun.
Does that make sense?
the argument i think is being made towards that the short answer is no not everybody should be on the glp-1 glp-1s are tools okay they're not right they're not weight loss drugs that that that to me eli lilly and nova nordis should be pitching a fit because they're not weight loss drugs they're well beyond that and we see that in the data right the impact on reducing the risk of cardiovascular disease all these things but as a purist as a nerd at heart
you have to look at what we call mechanisms of action.
Showing 1421–1440 of 2,131 · page 72 of 107
← Previous
Next →